Immunology

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Retrieved on: 
Monday, January 22, 2024

In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.

Key Points: 
  • In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.
  • In DENALI, AIRSUPRA had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.2
    The approach to treating asthma symptoms with rescue has changed.
  • The 2023 Global Initiative for Asthma (GINA) report supports a rescue approach that treats both symptoms and inflammation together.
  • Now, with AIRSUPRA available we can provide patients, especially those on maintenance therapy, another rescue option for managing their breakthrough symptoms.

VectorY Appoints Khurem Farooq to Board of Directors

Retrieved on: 
Thursday, January 18, 2024

VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective immediately.

Key Points: 
  • VectorY Therapeutics, a biotech company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of industry veteran Khurem Farooq as independent board member, effective immediately.
  • Khurem Farooq is an accomplished industry leader who brings more than 20 years of operational and drug development experience.
  • He currently serves as the CEO at Aiolos Bio which recently announced an agreement to be acquired by GSK.
  • Sander van Deventer, CEO of VectorY, commented: “We are delighted to welcome Khurem to VectorY as an independent board member.

ImmunoBrain Checkpoint Appoints Dr. Sanjay Keswani as Chief Executive Officer

Retrieved on: 
Monday, January 22, 2024

NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.

Key Points: 
  • NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
  • Dr. Keswani is an accomplished physician-scientist with executive leadership experience in both large pharma and small biotech companies.
  • "As a physician-scientist and seasoned biotech executive, Dr. Keswani possesses both the business acumen and the R&D expertise required to serve as Chief Executive Officer of ImmunoBrain," stated Nathan Hevrony, Co-founder and Executive Chairman of ImmunoBrain.
  • I am privileged to work with the ImmunoBrain team and Professor Michal Schwartz whose groundbreaking seminal research has formed the foundation of ImmunoBrain," stated Dr. Sanjay Keswani.

Immunitas Therapeutics Appoints Annalisa D'Andrea, Ph.D., as Chief Scientific Officer

Retrieved on: 
Thursday, January 18, 2024

WALTHAM, Mass., Jan. 18, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of Annalisa D'Andrea, Ph.D., as Chief Scientific Officer (CSO). Dr. D'Andrea has more than 25 years of basic and translational research and development expertise in both large and small pharmaceutical and biotech settings.

Key Points: 
  • Dr. D'Andrea brings more than 25 years of research and development experience to the company, expanding executive leadership team to advance pipeline
    WALTHAM, Mass., Jan. 18, 2024 /PRNewswire/ -- Immunitas Therapeutics ("Immunitas"), a clinical stage precision immunotherapy company committed to discovering and developing novel, differentiated therapeutics for patients with cancer, today announced the appointment of Annalisa D'Andrea, Ph.D., as Chief Scientific Officer (CSO).
  • Dr. D'Andrea brings to Immunitas a strong history of success in immunology therapeutic development, having led products from target selection through clinical evaluation.
  • "Annalisa's leadership and deep drug development expertise has proven invaluable as we advanced our growing pipeline of novel precision immuno-oncology therapeutics over the past several months," said Amanda Wagner, Chief Executive Officer of Immunitas.
  • "We are excited to welcome her as our full-time Chief Scientific Officer.

Advanced Lateral Flow Conference 2024 Innovation Award Finalists Announced

Retrieved on: 
Tuesday, January 16, 2024

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, has announced the finalists for its 2024 Innovation Awards.

Key Points: 
  • SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- DCN Dx, a global leader in the end-to-end development, manufacturing, and commercialization of point-of-use tests, has announced the finalists for its 2024 Innovation Awards.
  • The awards will be presented at the Advanced Lateral Flow Conference (ALFC) 2024.
  • Innovation Award finalists will pitch their entries to the ALFC audience on the first day of the event (Feb. 13, 2024).
  • For more information about the Advanced Lateral Flow Conference, visit alfc2024.com.

Enveda Biosciences Announces Therapeutic Advisory Board Chaired by Nicholas Saccomano, Ph.D.

Retrieved on: 
Wednesday, January 10, 2024

Enveda Biosciences, a biotechnology company using AI and advanced technologies to translate nature’s chemistry into new medicines, today announced the formation of a Therapeutic Advisory Board (TAB), chaired by Nicholas Saccomano, Ph.D.

Key Points: 
  • Enveda Biosciences, a biotechnology company using AI and advanced technologies to translate nature’s chemistry into new medicines, today announced the formation of a Therapeutic Advisory Board (TAB), chaired by Nicholas Saccomano, Ph.D.
  • “This is an incredibly exciting time for Enveda as we launch our first trials for multiple lead assets and transition into a clinical-stage company.
  • The formation of the TAB marks a significant milestone for Enveda Biosciences as they advance their first assets for a range of inflammatory and neurosensory conditions.
  • Founded in 2019, the company plans to launch at least two clinical trials in 2024.

City of Hope Research Reveals an Immune Cell That Can Attack Cancer

Retrieved on: 
Wednesday, January 10, 2024

According to preclinical research published online today in Cell , one of the world’s premier scientific journals, researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.

Key Points: 
  • According to preclinical research published online today in Cell , one of the world’s premier scientific journals, researchers with City of Hope®, one of the largest cancer treatment and research organizations in the United States, have discovered that a type of immune cell in the human body known to be important for allergy and other immune responses can also attack cancer.
  • View the full release here: https://www.businesswire.com/news/home/20240109475331/en/
    City of Hope researchers discovered that ILC2s, pictured here, can attack cancer cells.
  • However in the highly translational labs at City of Hope, researchers prioritized the examination of human cells and found that human ILC2s do not work the same as mouse ILC2s.
  • In fact, Yu is founding director of the Natural Killer Cell Biology Research Program at City of Hope, a national leader in the field.

Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases

Retrieved on: 
Tuesday, January 9, 2024

“We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.

Key Points: 
  • “We are excited to extend the utility of our allogeneic CAR T assets into immunology by collaborating with TG Therapeutics as they advance novel treatments for B-cell diseases.
  • Precision will also receive $2.5 million within 12 months, as an equity investment in Precision’s common stock at 100% premium to the then 30-day VWAP prior to purchase.
  • Upon the achievement of certain near-term clinical milestones, Precision will receive an additional $7.5 million payment in cash and the purchase of Precision common stock by TG Therapeutics at a 100% premium to the then current 30-day VWAP.
  • These transactions are expected to extend our runway and will fund continued development of our wholly owned in vivo gene editing programs.

Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors

Retrieved on: 
Monday, January 8, 2024

Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D.

Key Points: 
  • Nuvation Bio Inc. (NYSE: NUVB), a biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced the appointment of Robert Mashal, M.D.
  • “We are delighted to have Dr. Mashal join our Board of Directors,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio.
  • “Robert is a seasoned biotech industry veteran and his experience as an investor, operator, and medical oncologist will provide us with valuable insights.
  • We look forward to working with Robert to advance Nuvation’s pipeline.”
    “Nuvation Bio is at the forefront of developing therapeutic candidates to treat the unmet need in oncology, highlighted by the company’s novel drug-drug conjugate platform,” said Robert Mashal, M.D.

Be Biopharma Expands Leadership Team as Company Transitions to Clinical Stage Organization

Retrieved on: 
Thursday, January 4, 2024

Mr. Smith also brings nearly a decade of investment banking experience, providing strategic and financial advice across the healthcare sector.

Key Points: 
  • Mr. Smith also brings nearly a decade of investment banking experience, providing strategic and financial advice across the healthcare sector.
  • “We are thrilled to welcome Angus and Wing to Be Bio,” said Joanne Smith-Farrell, Ph.D., Chief Executive Officer.
  • These accomplished and experienced leaders will further strengthen our leadership team.
  • During his nearly decade-long investment banking tenure, Mr. Smith provided strategic and financial advice to life sciences and healthcare companies.